Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly & Co. is tapping the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of ...

Eli Lilly's innovative culture and strong financial ... Lilly is developing a new Alzheimer’s drug (Kisunla/donanemab) that could become a major blockbuster, especially since few treatment ...

Eli Lilly's Q4 FY24 guidance adjustment is due ... In the neuroscience space, Lilly has made significant strides with donanemab. The TRAILBLAZER-ALZ 6 trial showed positive results, bringing ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

Nico Chen’s rating is based on a combination of factors that highlight Eli Lilly & Co’s promising ... for diabetes and weight loss, and Donanemab for Alzheimer’s disease.

We maintain Eli Lilly’s High Uncertainty Rating ... including level of insurance coverage and pricing. Alzheimer’s drug donanemab holds the potential to become another major new drug, but ...